Zacks Investment Research on MSN

Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings

Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...

Eli Lilly Sues 2 Texas Companies Over Weight Loss Drug Replicas

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multi-state battle to stop sales of replica ...
Contract Pharma

Lilly Agrees to Acquire Adverum Biotechnologies

Eli Lilly and Company has agreed to acquire Adverum Biotechnologies Inc., a clinical-stage company pioneering the use of intravitreal gene therapy.
KSHB Kansas City

Eli Lilly warns 2 of its insulin products may be out of stock

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro ...

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?

Eli Lilly is a leader in weight loss drugs, a market that may reach $95 billion by the end of the decade. Viking Therapeutics ...

Should You Buy Eli Lilly Stock Before Oct. 30?

On Aug. 7, 2025, Lilly reported Q2 earnings results that were 12.9% higher than the average estimate. That might seem to be ...

Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more about LLY stock here.

Lilly to Acquire Adverum Biotechnologies

Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life ...